Equipped with state-of-the-art technologies in ultrasensitive immunoassays and mass spectrometry, along with our extensive clinical resources, we are dedicated to revolutionizing biomarker research in neurodegenerative diseases to transform the clinical management of dementia and improve patient outcomes.